Cytokines, adhesion molecules, antiendothelial cell autoantibodies and vascular disease

Cardiovascular Pathology

Volumn 6, Issue 2, 1997, Pages 61-78

  Carvalho, Dulce ^a   Savage, Caroline ^b  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CELL ADHESION MOLECULE; CYTOKINE;

ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

EID: 0030898487     PISSN: 10548807     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-8807(96)00065-8     Document Type: Review

References (318)

1. Celi A, Pellegrini G, Lorenzet R, et al. P-selectin induces the expression of tissue factor on monocytes. Proc Natl Acad Sci USA 1994; 91:8767-8777.
2. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995;375:517-519.
3. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-451.
4. Tuder RM, Weinberg A, Panajotopoulos N, Kalil J. Cytomegalovirus infection amplifies class I major histocompatibility complex expression on cultured human endothelial cells. J Heart Lung Transplant 1994;13:129-138.
5. Woodroffe SB, Garnett HM, Layton JE. Cytomegalovirus infection of vascular endothelial cells alters production of GM-CSF and G-CSF. Immunol Cell Biol 1994; 72:187-190.
6. Bradley JR. The immunological role of the endothelium in organ transplantation. In: Savage COS, Pearson JD, eds. Immunological Aspects of the Vascular Endothelium. Cambridge University Press, 1995;233-252.
7. Springer TA. Traffic signals for lymphocyte and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
8. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. Faseb J 1994;8:504-512.
9. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-2101.
10. Blixt M. Microscopic studies on the influence of erythrocyte concentration at small venules bifurcations. Int J Microcirc Clin Exp 1985; 4:141-156.
11. Mulligan MS, Poley MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA. Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest 1990:90:1600-1607.
12. Weyrich AS, Ma X-L, Lefer DJ, Albertine KH, Lefer AM. In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischaemia and reperfusion injury. J Clin Invest 1993; 91:2620-2629.
13. + T lymphocytes on tumor necrosis factor alpha-activated vascular endothelium under flow. J Exp Med 1995;181:1179-1186.
14. Alon R, Rossiter H, Wang X, Springer TA, Kupper TS. District cell surface ligands mediate T lymphocyte attachment and rolling on P and E selectin under physiological flow. J Cell Biol 1994;127:1485-1495.
15. Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993;91:379-387.
16. Tedder TF, Steeber DA, Chen A, Engel P. The selectins: vascular adhesion molecules. Faseb J 1995;9:866-873.
17. Fiebig E, Ley K, Arfors KE. Rapid leukocyte accumulation by spontaneous rolling and adhesion in the exteriorized rabbit mesentery. Int J Microcirc Clin Exp 1991;10:127-144.
18. Mayrovitz HN. Leukocyte rolling: a proeminent feature of venules in intact skin of anesthetized hairless mice. Am J Physiol 1992;262: H157-H161.
19. McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet α granule, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest 1989;84:92-99.
20. Dore M, Korthuis RJ, Granger DN, Entman ML, Smith CN. P-selectin mediates spontaneous leukocyte rolling in vivo. Blood 1993;82: 1308-1310.
21. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem 1989;264:9053-9060.
22. Foreman KE, Vaporciyan AA, Bonish BK, et al. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest 1994;94:1147-1155.
23. Bienvenu K, Granger DN. Molecular determinants of shear rate-de-pendent leukocyte adhesion in postcapillary venules. Am J Physiol 1993;264:H1504-H1508.
24. Bevilacqua BS, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci USA 1987;84:9238-9242.
25. Damle NK, Eberhardt C, Van der Vieren M. Direct interaction with primed CD4+ CD45RO+ memory lymphocytes induces expression of endothelial leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1 on the surface of vascular endothelial cells. Eur J Immunol 1991;21:2915-2923.
26. Lawrence MB, Springer TA. Neutrophils roll on E-selectin. J Immunol 1993;151:6338-6346.
27. Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P-selectin-deficient mice. Cell 1993;74:541-554.
28. Olofsson AM, Arfors K-E, Ramezani L, Wolitsky BA, Butcher EC. E-selectin mediates leukocyte rolling in interleukin-1 treated rabbit mesentery venules. Blood 1994;84:2749-2758.
29. von Andrian UH, Hansel P, Chambers JD, et al. L-selectin function is required for β2 integrin-mediated neutrophil adhesion at physiological shear rates in vivo. Am J Physiol 1992;263:H1034-H1044.
30. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. Faseb J 1990;4:2868-2880.
31. Luscinskas FW, Kiely J-M, Ding H, et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. J Immunol 1992;149:2163-2172.
32. von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors K-E, Butcher EC. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte β2 integrins in vivo. Proc Natl Acad Sci USA 1991;88:7538-7542.
33. Perry MA, Granger DN. Role of CD11/CD18 in shear rate-dependent leukocyte-endothelial cell interactions in cat mesenteric venules. J Clin Invest 1991;87:1798-1804.
34. Dustin ML, Rothlein R, Bahn AK, Dinarello CA, Springer TA. Induction by IL-1 and interferon-gamma: tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986;137:245-254.
35. Lo SK, van seventer GA, Levin SM, Wright SD. Two transient receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands. J Immunol 1989; 143: 3325-3329.
36. Argenbright LW, Letts LG, Rothlein R. Monoclonal antibodies to the leukocyte membrane CD18 glycoprotein complex and to intercellular adhesion molecule-1 inhibit leukocyte-endothelial adhesion in rabbits. J Leukocyte Biol 1991;49:253-257.
37. Nortamo P, Li R, Renkonen R, et al. The expression of human intercellular adhesion molecule 2 is refractory to inflammatory cytokines. Eur J Immunol 1991;21:2629-2632.
38. Osborn L, Hession C, Tizard R, et al. Direct expression clonning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-1211.
39. Thornhill MH, Kyan-Aung U, Haskard DO. IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. J Immunol 1990;144:3060-3065.
40. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin. Cell 1990;60:577-584.
41. Vonderheide RH, Springer TA. Lymphocyte adhesion through very late antigen 4: evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional α4 integrin counter-receptor on stimulated endothelium. J Exp Med 1992;175:1433-1439.
42. Li Y-Y, Cheung HT. Basement membrane and its components on lymphocyte adhesion, migration and proliferation. J Immunol 1992; 149:3174-3183.
43. Kavanaugh AF, Lightfoot E, Lipsky PE, Oppenheimer-Marks N. Role of CD11/CD18 in adhesion and transendothelial migration of T cells. J Immunol 1991;146:4149-4156.
44. Muller WA, Weigl SA. Monocyte-selective transendothelial migration: dissection of the binding and transmigration phases by an in vitro assay. J Exp Med 1992;176:829-835.
45. Bianchi G, Sironi M, Ghibaudi E, et al. Migration of natural killer cells across endothelial cell monolayers. J Immunol 1993;151:5135-5144.
46. Hakkert BC, Kuijpers TW, Leeuwenberg JFM, van Mourik JA, Roos D. Neutrophil and monocyte adherence to and migration across monolayers of cytokine-activated endothelial cells: the contribution of CD18, ELAM-1, and VLA-4. Blood 1991;78:2721-2726.
47. Meerschaert J, Furie MB. The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/ CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol 1995;154:4099-4112.
48. Oppenheimer-Marks N, Davis LS, Bogue DT, Ramberg J, Lipsky PE. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol 1991;147:2913-2921.
49. Winn RK, Harlan JM. CD18-independent neutrophil and mononuclear leukocyte emigration into the peritoneum of rabbits. J Clin Invest 1993;92:1168-1173.
50. DeLisser HM, Newman PJ, Albelda SM. Molecular and functional aspects of PECAM-1/CD31. Immunol Today 1994;15:490-495.
51. Albelda SM, Muller WA, Buck CA, Newman PJ. Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. J Cell Biol 1990;114:1059-1068.
52. Muller WA, Weigl SA, Deng X, Philips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178: 449-460.
53. Vaporciyan AA, DeLisser HM, Yan H-C, et al. Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science 1993;262:1580-1582.
54. Bogen S, Pak J, Garifallou M, Deng X, Muller WA. Monoclonal antibody to murine PECAM-1 (CD31) blocks acute inflammation in vivo. J Exp Med 1994;179:1059-1064.
55. Bird IN, Spragg JH, Ager A, Mathews N. Studies of lymphocyte transendothelial migration: analysis of migrated cell phenotypes with regard to CD31 (PECAM-1), CD45RA, and CD45RO. Immunol 1993;80:553-561.
56. Muller WA. The role of PECAM-1 (CD31) in leukocyte emigration: studies in vitro and in vivo. J Leukocyte Biol 1995;57:523-528.
57. Zimmerman GA, McIntyre TM, Mehra M, Prescott SM. Endothelial cell-associated platelet activating factor: a novel mechanism for signalling intercellular adhesion. J Cell Biol 1990;110:529-540.
58. Lorant D, Topman MK, Whatley RE, et al. Inflammatory roles of P-selectin. J Clin Invest 1993;92:559-570.
59. Lorant DE, Patel KD, McIntyre TM, et al. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine and thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Clin Invest 1991;115:223-234.
60. Zimmerman GA, Prescott SM, McIntyre TM. Endothelial cell interactions with granulocytes: tethering and signalling molecules. Immunol Today 1992;13:93-99.
61. Rot A. Endothelial cell binding of NAP-1/IL-8: role in neutrophil emigration. Immunol Today 1992;13:291-294.
62. Huber AR, Kunkel SL, Tod RF, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991;253:1-4.
63. Williams GM, Lee DM, Weymouth RF, et al. Studies in hyperacute and chronic renal homograft rejection in man. Surgery 1967;62:204-212.
64. Williams GM, ter Haar A, Parks LC, Krajewski CA. Endothelial changes associated with hyperacute, acute and chronic rejection in man. Transplant Proc 1973;5:819-822.
65. Nourshargh S. Mechanisms of neutrophil and eosinophil accumulation in vivo. Am Rev Resp Dis 1993;148:560-564.
66. Mampaso F, Sanchez-Madrid F, Marcen R, et al. Expression of adhesion molecules in allograft renal dysfunction: a distinct diagnostic pattern in rejection and cyclosporine nephrotoxicity. Transplantation 1993;56:687-691.
67. Furie MB, Randolph GJ. Chemokines and tissue injury. 1995. Am J Pathol 1995;146:1287-1301.
68. Schall TJ. Biology of the RANTES/SIS cytokine family. Cytokine 1991;3:165-183.
69. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today 1993;14:111-115.
70. Cockwell P, Adams DH, Savage COS. 1996. Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Clin Exp Immunol 1996;104:1-3.
71. Savage COS, Hughes CCW, McIntyre BW, Picard JK, Pober JS. Human CD4+ T cells proliferate to HLA-DR+ allogeneic vascular endothelium: Identification of accessory interactions. Transplantation 1993;56:128-134.
72. Page CS, Holloway N, Smith H, Yacoub M, Rose ML. Alloproliferative responses of purified CD4+ and CD8+ T cells to endothelial cells in the absence of containing accessory cells. Transplantation 1994;57:1628-1637.
73. Messadi DV, Pober JS, Murphy GF. Effects of recominant γ-interferon on HLA-DR and DQ expression by skin cells in short-term organ cultures. Lab Invest 1988;58:61-67.
74. Hughes CCW, Savages COS, Pober JS. The endothelial cell as a regulator of T-cell function. Immunol Rev 1990;117:85-102.
75. Pober JS, Collins T, Gimbrone MA, Libby P, Reiss CS. Inducible expression of class II histocompatibility complex antigens and the immunogenicity of vascular endothelium. Transplantation 1983; 41: 141-146.
76. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-γ induce distinct patterns of endothelial activation and leukocyte accumulation in skin of Papio anubis. Am J Path 1988;135: 121-133.
77. Pardi R, Bender JR, Engleman EG. Lymphocyte subsets differentially induce class II human leukocyte antigens on allogeneic microvascular endothelial cells. J Immunol 1987;139:2582-2592.
78. + T cells inhibit EC class II MHC expression despite secreting IFN-γ and increasing EC class I MHC and intercellular adhesion molecule-1 expression. J Immunol 1990;145: 1088-1098.
79. Watson CA, Petzelbauer P, Zhou J, Pardi R, Bender JR. Contact-dependent endothelial class II HLA gene activation induced by NK cells is mediated by IFN-gamma-dependent and -independent mechanisms. J Immunol 1995;154:3222-3233.
80. Brooks CJ, Stackpoole A, Savage COS. Synergistic interactions of CD4+ and CD8+ T cell subsets with human vascular endothelial cells in primary proliferative allogeneic responses. Int Immunol 1994;5:1041-1048.
81. Savage COS, Brooks CJ, Harcourt GC, et al. Human vascular endothelial cells process and present autoantigen to human T cell lines. Int Immunol 1995;7:471-479.
82. Hughes CCW, Savage COS, Pober JS. Endothelial cells augment T cell interleukin 2 production by a contact-dependent mechanism involving CD2/LFA-3 interaction. J Exp Med 1990;171:1453-1467.
83. + T cells. Cell Immunol 1991;137:150-158.
84. Westphal JR, Willems HM, Tax WJM, Koene RAP, Ruiter DJ, Waal RMW. Endothelial cells promote anti-CD3-induced T-cell proliferation via cell-cell contact mediated by LFA-1 and CD2. Scand J Immunol 1993;38:435-444.
85. Cid MC, Esparza J, Juan M, et al. Signalling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in β1 and β2 integrin function. Eur J Immunol 1994;24:1377-1382.
86. Gearing AJH, Newman W. Circulating adhesion molecules in disease. Immunol Today 1993;14:506-512.
87. Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. Endothelial-leukocyte adhesion molecules in human disease. Annu Rev Med 1994; 45:361-378.
88. Leeuwenberg JFM, Smeets EF, Neefjes JJ, et al. E-selectin and intercellular adhesion molecule are released by activated human endothelial cells in vitro. Immunology 1992;77:543-549.
89. Pigott R, Dillon LP, Hemingway IK, Gearing AJH. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commum 1992;187:584-589.
90. Newman W, Beall LD, Carson CW, et al. Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with sepsis. J Immunol 1993;150:644-654.
91. Lobb RR, Chi-Rosso G, Leone DR, et al. Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1. J Immunol 1991;147:124-129.
92. Martin SD, Staunton DE, Springer TA, Stratowa C, Sommerguber W, Merluzzi VJ. A soluble form of intercellular adhesion molecule 1 inhibits rhinovirus infection. Nature 1990;344:70-72.
93. Mantovani A, Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 1989;10: 370-375.
94. Dinarello CA. Interleukin-1 and its biologically related cytokines. Immunol Rev 1992;127:119-134.
95. Dinarello CA. The interleukin-1 family: 10 years of discovery. Faseb J 1994;8:1314-1325.
96. Libby P, Ordovas JM, Auger KR, Robbins AH, Birinyi LK, Dinarello CA. Endotoxin and tumor necrosis factor induce interleukin gene expression in adult human vascular endothelial cells. Am J Pathol 1986;124:179-185.
97. Kurt-Jones EA, Fiers W, Pober JS. Membrane IL-1 induction on human endothelial cells and dermal fibroblasts. J Immunol 1987;139: 2317-2324.
98. Kupper TS, Groves RW. The interleukin-1 axis and cutaneous inflammation. J Invest Dermatol 1995;105:62S-66S.
99. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993;11:767-804.
100. Colotta F, Sironi M, Borre A, Luini W, Maddalena F, Mantovani A. Type II interleukin-1 receptor is not expressed in cultured endothelial cells and is not involved in endothelial cell activation. Blood 1993; 81:1347-1357.
101. Rossi V, Breviario F, Ghezzi P, Dejana E, Mantovani A. Prostacyclin synthesis induced in vascular cells by interleukin-1. Science 1985; 229:174-176.
102. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990;75:688-695.
103. Nachman RL, Hajjar KA, Silverstein RL, Dinarello CA. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986;163:1595-1600.
104. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Interleukin 1 and tumor necrosis factor activation of vascular endothelium: effects on plasminogen activator inhibitor and tissue-type plasminogen activator. J Biol Chem 1988;263:5797-5803.
105. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 1986;83:3460-3464.
106. Bussolino F, Breviario F, Tetta C, Aglietta M, Mantovani A, Dejana E. Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest 1986;77:2027-2038.
107. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049-9054.
108. Warner SJC, Auger KR, Libby P. Interleukin induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by human vascular endothelial cells. J Immunol 1987;139:1911-1917.
109. Sironi M, Breviario F, Proserpio P, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol 1989;142:549-553.
110. Strieter RM, Kunkel SL, Showell HJ, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-α, LPS, and IL-1β. Science 1989;243:1467-1469.
111. Strieter RM, Wiggins R, Phan SH, et al. Monocyte chemotactic protein gene expression by cytokine treated human fibroblasts and endothelial cells. Biochem Biophys Res Commun 1989;162:694-700.
112. Broudy VC, Kauskansky K, Harlan JM, Adamson JW. Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factors and granulocyte colony-stimulating factor. J Immunol 1988;139:464-468.
113. Rosenkranz-Weiss P, Sessa WC, Milstien S, Kaufman S, Watson CA, Pober JS. Regulation of nitric oxide synthesis by proinflammatory cytokines in human umbilical vein endothelial cells. Elevations in tetrahydrobiopterin levels enhance endothelial nitric oxide synthase specific activity. J Clin Invest 1994;93:2236-2243.
114. Postlethwaite AE, Lachman LB, Kang AH. Induction of fibroblast proliferation by interleukin 1 derived from human monocytic leukemia cells. Arthritis Rheum 1984;27:995-1001.
115. Goldring MB, Krane SM. Modulation by recombinant interleukin 1 of synthesis of types I and III collagens and associated procollagen mRNA levels in cultured human cells. J Biol Chem 1987;262:16724-16729.
116. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989;243:393-394.
117. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991;97:686-692.
118. Williams JM, DeLoria D, Hansen JA, et al. The events of primary T cell activation can be staged by use of sepharose-bound anti-T3(64.1) monoclonal antibody and purified interleukin-1. J Immunol 1985; 135:2249-2255.
119. Kaye J, Gillis S, Mizel SB. Growth of a cloned T cell line induced by monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for IL-2. J Immunol 1984;133:1339-1345.
120. Cavender DE, Haskard DO, Joseph B, Ziff M. Interleukin 1 increases the binding of B and T lymphocytes to endothelial cell monolayers. J Immunol 1986;136:203-207.
121. Lorre K, Kasran A, van Vaeck L, de Boer M, Ceuppens JL. Interleukin-1 and B7/CD28 interaction regulate interleukin-6 production by human T cells. Clin Immunol Immunopathol 1994;70:81-90.
122. Navarro S, Debili N, Bernandi JF, Vainchenker W, Doly J. Regulation of the expression of IL-6 in human monocytes. J Immunol 1989; 142:4339-4345.
123. Philip R, Epstein LB. Tumor necrosis as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma interferon and interleukin 1. Nature 1986;322:86-89.
124. Jirik FR, Podor TJ, Hirano T, et al. Bacterial lipoplysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol 1989;142:144-147.
125. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
126. Kovacs EJ, Dipietro LA. Fibrogenic cytokines and connective tissue production. Faseb J 1994;8:854-861.
127. Oppenheim JJ, Zachatiae COC, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene intercrine cytokine family. Annu Rev Immunol 1991;9:617-648.
128. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2acetyl-sn-glycer-3-phosphocoline) when stimulated with thrombin. Proc Natl Acad Sci USA 1984;81:3534-3538.
129. Koltai M, Hosford D, Braquet P. Role of Paf and cytokines in microvascular tissue injury. J Lab Clin Med 1992;119:461-466.
130. McManus LM, Woodard DS, Deavers SI, Pinckard RN. PAF molecular heterogeneity: pathobiological implications. Lab Invest 1993;69: 639-648.
131. Li Y-S, Shyy Y-J, Wright JG, Valente AJ, Cornhill JF, Kolattukudy PE. The expression of monocyte chemotactic protein (MCP-1) in human vascular endothelium in vitro and in vivo. Mol Cell Biochem 1993;126:61-68.
132. Fibbe WE, Daha MR, Hiemstra PS, et al. Interleukin-1 and poly(rI)poly(rC) induce production of granulocyte CSF, macrophage CSF and granulocyte-macrophage CSF by human endothelial cells. Exp Haematol 1989;17:229-234.
133. Wang JM, Colella S, Allavena P, Mantovani A. Chemotactic activity of human recombinant granulocyte-macrophage colony-stimulating factor. Immunology 1987;60:439-444.
134. Wang MJ, Chen ZG, Colella S, et al. Chemotactic activity of recombinant human granulocyte colony-stimulating factor. Blood 1988;72: 1456-1460.
135. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cell synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990;136:1229-1233.
136. Colotta F, Sciacca FL, Sironi M, Luini W, Rabiet M, Mantovani A. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Am J Pathol 1994;144:975-985.
137. Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 1992;90:1-7.
138. Fontana A, Constam DB, Frei K, Malpiero U, Pfister HW. Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 1992;99:1-7.
139. Huang EH, Morgan CJ, Sedmak DD, Ferguson RM, Orosz CG. Alloantigenicity of human endothelial cells. IV. Derivation, characterization, and utilization of gonadal vein endothelia to control endothelial alloantigenicity during lymphocte-endothelial interactions. Transplantation 1994;57:703-711.
140. Sporn MB, Roberts AN. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 1986;78:329-332.
141. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 1988;332:217-219.
142. Kurihara H, Yoshizumi M, Sugiyama T, et al. Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem Biophys Res Commun 1989;159:1435-1440.
143. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788-5792.
144. Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-β. Science 1988;242:97-99.
145. Cai JP, Falanga V, Chin YH. Transforming growth factor-beta regulates the adhesive interactions between mononuclear cells and microvascular endothelium. J Invest Dermatol 1991;97:169-174.
146. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993;150:4494-4503.
147. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor-β is a potent immunosupressive agent that inhibits IL-1 dependent lymphocyte proliferation. J Immunol 1988;140:3026-3032.
148. Kehrl JH, Wakefield LM, Roberts AB, et al. Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-1050.
149. Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor β is an important immunomodulatory protein for human B Lymphocytes. J Immunol 1986; 137:3855-3860.
150. Brandes ME, Allen JB, Ogawa Y, Wahi S. Transforming growth factor β1 supresses acute and chronic arthritis in experimental animals. J Clin Invest 1991;87:1108-1113.
151. Kuruvilla AP, Shah R, Hochwald GM, Liggit HD, Palladino MA, Thorbecke GJ. Protective effect of transforming growth factor β1 on experimental autoimmune diseases in mice. Proc Natl Acad Sci USA 1991;88:2918-2921.
152. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β. J Exp Med 1990;171:231-247.
153. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J Exp Med 1987;165:251-256.
154. Ignotz RA, Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;262:4337-4345.
155. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor β (TGFβ) causes a persistent increase in steady-state amounts of type I and III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597-604.
156. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metaloproteinase inhibitor. EMBO J 1987;6:1899-1904.
157. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-4171.
158. Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986;46:155-169.
159. DiCorleto PE, Bowen-Pope DF. Cultured endothelial cells produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 1983;80:1919-1923.
160. Raines EW, Dower SK, Ross R. Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 1989;243:393-394.
161. Heldin C-H, Wasteson M, Westermark B. Platelet-derived growth factor. Mol Cell Biol 1985;3:169-187.
162. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987;325:257-259.
163. Baird A, Walicke PA. Fibroblast growth factor. Br Med Bull 1989; 45:438-452.
164. Lindqvist KJ, Osterland CK. Human antibodies to vascular endothelium. Clin Exp Immunol 1971;9:753-760.
165. Sordat B, Hess MW, Cottier H. IgG immunoglobulin in the wall of postcapillary venules: possible relationship to lymphocyte recirculation. Immunology 1971;20:115-118.
166. McCrae KR, Cines DB. Immunologic properties of antibodies to endothelial cells: relationship with antiphospholipids antibodies. In: Cervera R, Khamashta MA, Hughes GRV, eds. Antibodies to Endothelial Cells and Vascular Damage. Boca Raton, FL: CRC, 1994;47-70.
167. Homeland M, Rekvig OP, Jorgensen L, Hannestad K. Cultured human endothelial cells display an antigen that is recognized by certain human anti-chromatin autoantibodies. Clin Exp Immunol 1983;54: 373-377.
168. Yap HK, Sakai RS, Bahn L, et al. Anti-vascular endothelial cell antibodies in patients with IgA nephropathy: frequency and clinical significance. Clin Immunol Immunopathol 1988;49:450-462.
169. Chan TM, Frampton G, Staines N, Hobby P, Perry GJ, Cameron JS. Different mechanisms by which monoclonal anti-DNA antibodies bind to human endothelial cells and glomerular mesangial cells. Clin Exp Immunol 1992;88:68-74.
170. Mayet WJ, Csernok E, Szymkowiak C, Gross WL, Meyer zum Buschenfelde KH. Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood 1993;82:1221-1229.
171. Rosenbaum J, Pottinger BE, Woo P, Black CM, Byrons MA, Pearson JD. Measurement and characterization of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988;72: 450-456.
172. Cervera R, Khamashata MA, Font J, et al. Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 1991;11:1-6.
173. Hill MB, Phipps JL, Malia RG, Greaves M, Hughes P. Characterization and specificity of antiendothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS). Clin Exp Immunol 1995;102:368-372.
174. Simantov R, LaSala J, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995;96:2211-2219.
175. Aydintug AO, Tokgoz G, D'Cruz DP, et al. Antibodies to endothelial cells in patients with Behcet's disease. Clin Immunol Immunopathol 1993;67:157-162.
176. Del Papa N, Guidali L, Spatola L, et al. Relationship between antiphospholipid and anti-endothelial cell antibodies III: beta2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecule. Clin Exp Rheumatol 1995;13:179-185.
177. Holt CM, Lindsey N, Moult J, et al. Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 1989;78:359-365.
178. Hasselaar P, Derksen RHWM, Blokzijl L, de Groot PG. Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemostas 1990;63:169-173.
179. McCrae KR, DeMichelle A, Samuels P, et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 1991;79:592-605.
180. D'Cruz DP, Houssiau FA, Ramirez G, et al. Antibodies to endothelial cells in systemic lupus erythematosus: a potential marker for nephritis and vasculitis. Clin Exp Immunol 1991;85:254-261.
181. McCarty GA, Lister KA, Meroni PL. 1991. Independence to endothelial cells, phospholipids and neutrophil cytoplasmic antigen in systemic vasculitis. Arthritis Rheum 1991;34(Suppl):70.
182. Vismara A, Meroni PL, Tincani A, et al. 1988. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 1988;74:247-253.
183. Frampton G, Perry GJ, Cameron JS. 1994. Antibodies to endothelial cells in renal diseases and renal transplantation. In: Cervera P, Khamashata MA, Hughes GRV, eds. Antibodies to Endothelial Cells and Vascular Damage. Boca Raton, FL: CRC, 1994;135-163.
184. Ferraro G, Meroni PL, Tincani A, et al. Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis. Clin Exp Immunol 1990;79:47-53.
185. Frampton G, Jayne DRW, Perry GJ, Lockwood CM, Cameron JS. Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vaxculitis. Clin Exp Immunol 1990;82:227-232.
186. van der Zee JM, Heurkens AHM, van der Voort EAM, Daha MR, Breedveld FC. Characterization of anti-endothelial antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Rheumatol 1991;9:589-594.
187. Hashemi S, Smith CD, Izaguirre CA. Anti-endothelial cell antibodies: detection and characterization using a cellular enzyme-linked immunosorbent assay. J Lab Clin Med 1987;109:434-440.
188. Heurkens AHM, Hiemstra PS, Lafeber GJM, Daha MR, Breedveld FC. Anti-endothelial cell antibodies in patients with rheumatoid arthritis complicated by vasculitis. Clin Exp Immunol 1989;78:7-12.
189. Penning CA, French MAH, Rowell NR, Hughes P. Antibody-dependent cellular cytotoxicity of human vascular endothelium in systemic lupus erythematosus. J Clin Lab Immunol 1985;17:125-130.
190. Mayer O, Haim T, Dryll A, Ryckewaert A. Vascular endothelial cell injury in progressive systemic sclerosis and other connective diseases. Clin Exp Rheumatol 1983;1:29-35.
191. Majewski S, Blaszcyk M, Jablonska S, et al. Cytotoxic effects of sera from patients with systemic scleroderma: comparison of three different in vitro methods. Rheumatol Int 1990;10:65-72.
192. van der Zee JM, Siegert CE, de Vreede TA, Daha MR, Breedveld FC. Characterization of anti-endothelial cell antibodies in systemic lupus erythematosus (SLE). Clin Exp Immunol 1991;84:238-244.
193. Tan EM, Pearson CM. Rheumatic disease sera reactive with capillaries in the mouse kidney. Arthritis Rheum 1972;15:23-28.
194. Shingu M, Hurd ER. Sera from patients with systemic lupus erythematosus reactive with human endothelial cells. J Rheumatol 1981; 8:581-586.
195. Cervera R, Ramirez G, Fernadez-Sola J, et al. Antibodies to endothelial cells in dermatomyositis: association with interstitial lung disease Br Med J 1991;302:880-881.
196. Perry GJ, Elston T, Khouri NA, Chan TM, Cameron JS, Frampton G. Antiendothelial cell antibodies in lupus: correlations with renal injury and circulating markers of endothelial damage. Q J Med 1993;86: 727-734.
197. Leung DYM, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 1986;77:1428-1435.
198. Tizard EJ, Baguley E, Hughes GRV, Dillon MJ. Antiendothelial cell antibodies detected by a cellular based ELISA in Kawasaki disease. Arch Dis Child 1991;66:189-192.
199. Cervera R, Navarro M, LopezSoto A, et al. Antibodies to endothelial cells in Behcet's disease: cell-binding heterogeneity and association with clinical activity. Ann Rheum Dis 1994;53:265-267.
200. Chan TM, Frampton G, Jayne DR, Perry GJ, Locksood CM, Cameron JS. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993;22:387-392.
201. Leung DYM, Maske JL, Havenns PL, Kim M, Pober JS. Lytic antiendothelial cell antibodies in haemolytic-uraemic syndrome. Lancet 1988;23:183-185.
202. Frank MM, Lawlwy TJ, Hamburger MI, Brown EJ. Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med 1983;98:206-218.
203. Schifferli JA, Ng YC. The role of complement in the processing of immune complex. Bailliere's Clin Immunol Allergy 1988;2:319-334.
204. Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int 1989;35:993-999.
205. Brisson C, Archipoff G, Hartmen ML, et al. Antibodies to thrombomodulin induce receptor-mediated endocytosis in human saphenous vein endothelial cells. Thromb Haemostas 1992;68:737-743.
206. Forsyth KD. Anti-CD9 antibodies augment neutrophil adherence to endothelium. Immunology 1991;72:292-296.
207. Del Papa N, Conforti G, Gambini D, et al. Characterization of the endothelial surface proteins recognized by anti-endothelial antibodies in primary and secondary autoimmune vasculitis. Clin Immunol Immunopathol 1994;70:211-216.
208. Cines DB, Lyss AP, Reeber M, Bina M, DeHoratius RJ. Presence of complement-fixing anti-endothelial cell antibodies in systemic lupus erythematosus. J Clin Invest 1984;73:611-625.
209. Wangel AG, Temonen M, Brummer-Korvenkontio M, Vaheri A. Anti-endothelial cell antibodies in nephropathia epidemica and other viral diseases. Clin Exp Immunol 1992;90:13-17.
210. Del Papa N, Meroni PL, Barcellini W, et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol 1992;63:267-274.
211. Heurkens AHM, Gorter A, Vreede TM, Edgell CS, Breedveld FC, Daha MR. Methods for the detection of anti-endothelial antibodies by enzyme-linked immunosorbent assay. J Immunol Methods 1991;141: 33-39.
212. Brasile L, Kremer JM, Clarke JL. Identification of an autoantibody to vascular endothelial cell-specific antigens in patients with systemic vasculitis. Am J Med 1989;87:74-80.
213. Koenig DW, Barley Maloney L, Daniel TO. A western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies. J Clin Immunol 1993;13:204-211.
214. Ma J, Chapman GV, Chen SL, Melick G, Penny R, Breit SN. Antibody penetration of viable human cells. I. Increased penetration of human lymphocytes by anti-RNP IgG. Clin Exp Immunol 1991;84:83-91.
215. Vlahakos D, Foster MH, Ucci AA, Barret KJ, Datta SK, Madaio M. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992;2:1345-1351.
216. Frampton G, Walker RG, Perry GJ, Harada T, Cameron JS. IgA affinity to ssDNA or endothelial cells and its deposition in glomerular capillary walls in IgA nephropathy. Nephrol Dial Transplant 1990;5:841.
217. Wang MX, Walker RG, Kincaid-Smith P. Endothelial cell antigens recognized by IgA autoantibodies in patients with IgA nephropathy: partial characterization. Nephrol Dial Transplant 1992;7:805-810.
218. Tanaka Y, Tskuda N, Koh Ch-S, Yanagisawa N. Antiendothelial cell antibodies and circulating immune complexes in the sera of patients with multiple sclerosis. J Neuroimmunol 1987;17:49-59.
219. Tsukada N, Yanagisawa N, Mochizuki I. Endothelial cell damage in sarcoidosis and neurosarcoidosis: autoantibodies to endothelial cells. Eur Neurology 1995;35:108-112.
220. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenia purpura on platelets and cultured vascular endothelial cells. Blood 1982;60:1030-1037.
221. Swerlick RA, Lee KH, Wick TM, Lawley TJ. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro. J Immunol 1992;148:78-83.
222. Tandon NN, Rock G, Jamieson GA. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura. Br J Haematol 1994;88:816-825.
223. Aiken ML, Ginsberg MH, Byers-Ward V, Plow EF. Effects of OKM5, a monoclonal antibody to glycoprotein IV on the platelet aggregation and thrombospondin surface expression. Blood 1990;76: 2501-2509.
224. Nakajima T, Koyama T, Kakishita E, Nagai K. Inhibitory effects of TTP sera on binding of anti-platelet glycoprotein IIb-IIIa monoclonal antibodies to human vascular endothelial cells. Am J Hematol 1987; 25:115-118.
225. Jallu V, Pico M, Chevaleyre J, Vezon G, Kunicki TJ, Nurden AT. 1992. Characterization of an antibody to the integrin beta3 subunit (GPIIIa) from a patient with neonatal thrombocytopenia and an inherited deficiency of GP IIb-IIIa complexes in platelets (Glanzmann's thrombasthenia). Hum Antibodies Hybridomas 1992;3:93-106.
226. Hashemi S, Drouin J, Trudel E, et al. Characterization of novel platelet and endothelial cell target antigens in a family with genetic susceptibility to autoimmunity. Am J Hematol 1991;38:293-303.
227. Cines DB, Tomaski A, Tannenbaum SH. Immune endothelial cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;16: 581-589.
228. Hasselaar P, Derksen RHWM, Oostings JD, Blokzijl L, de Groot PG. Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemostas 1989;62:654-660.
229. Shibata S, Harpel P, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 1994;83:2532-2540.
230. Shibata S, Sasaki T, Harpel P, Fillit H. Autoantibodies to vascular haparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-anti-thrombin in complexes. Clin Immunol Immunopathol 1994;70:114-123.
231. Jackson RL, Brusch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions, and the role in physiological processes. Physiol Rev 1991;71:481-539.
232. David G. Structural and functional diversity of the heparan sulfate proteoglycans. Adv Exp Med Biol 1992;313:69-77.
233. Faaber P, Rijke TPM, van de Putte LBA, Capel PJA, Berden JHM. Cross-reactivity of human and murine anti-DNA antibodies with heparan sulfate. The major glycosaminoglycan in glomerular basement membrane. J Clin Invest 1986;77:1824-1830.
234. Pengo V, Biasiolo A, Fior MG. Binding of autoimmune cardiolipin-reactive antibodies to heparin: a mechanism of thrombosis. Thromb Res 1995;78:371-378.
235. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-associated thrombocytopenia. Thromb Haemostas 1992;68:95-96.
236. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81-88.
237. Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, MuellerEckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thrombin Haemostasis 1994;71:247-251.
238. Jacob L, Letty MA, Bach JF, Louvard D. Human systemic lupus erythematosus sera contain antibodies against cell-surface protein(s) that share(s) epitope(s) with DNA. Proc Natl Acad Sci USA 1986;83: 6970-6977.
239. Jacob L, Letty MA, Louvard D, Bach JF. Binding of a monoclonal anti-DNA autoantibody to identical protein(s) present at the surface of several human cell types involved in lupus pathogenesis. J Clin Invest 1985;75:315-317.
240. Kobayashi S, Haruta K, Takano Y, Akimoto T, Takasaki Y, Hashimoto H. Role of anti-thrombomodulin autoantibodies in schleroderma. Arthritis Rheum 1995;38:S609.
241. Kain R, Matsui K, Exner M, et al. A novel class of autoantigens of anti-neutrophil cytoplasmic antibodies in necrotizing and crescentic glomerulonephritis: the lysosomal membrane glycoprotein h-lamp-2 in neutrophil granulocytes and a related membrane protein in glomerular endothelial cells. J Exp Med 1995;181:585-597.
242. King WJ, Adu D, Daha MR, et al. Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3. Clin Exp Immunol 1995;102:98-105.
243. Falk RJ, Terrell RS, Charles LA, Jennette JC. Antineutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990;87:4115-4119.
244. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase-3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992;141:335-342.
245. Leung DYM, Geha RS, Newburger JW, et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986;164:1958-1964.
246. Kaneko K, Savage COS, Pottinger BE, Shah V, Pearson JD, Dillon MJ. Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. Clin Exp Immunol 1994;98: 264-269.
247. Savage COS, Pottinger BE, Gaskin G, Lockwood CM, Pusey CD, Pearson JD. Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti-endothelial cell antibodies and their relation to anti-neutrophil cytoplasm antibodies. Clin Exp Immunol 1991;85:14-19.
248. McCarty GA, Lister KA, Reichlin M, McEver R. Autoantibody to a novel endothelial cell granule membrane protein antigen in vasculitis. Clin Res 1990;38:316A.
249. Rappaport VJ, Hirata G, Yap HK, Jordan SC. Anti-vascular endothelial cell antibodies in severe preeclampsia. Am J Obstet Gynecol 1990;168:138-146.
250. van der Zee JM, Miltenburg AM, Siegert CE, Daha MR, Breedveld FC. Antiendothelial cell antibodies in systemic lupus erythematosus: enhanced antibody binding to interleukin-1-stimulated endothelium. Int Arch Allergy Immunol 1994;104:131-136.
251. Pearson JD. Autoantibodies to endothelial cells. In: Catravas J, Callow AR, Ryan US, eds. Vascular Endothelium. New York: Plenum Press, 1991;117-125.
252. Pearson JD. Antibodies to endothelial cells and vascular dynfunction in progressive systemic sclerosis and mixed connective tissue disease. In: Cervera P, Khamashta MA, Hughes GRV, eds. Antibodies to Endothelial Cells and Vascular Damage. Boca Raton, FL: CRC, 1994; 111-119.
253. Penning CA, Cunningham J, French MAH, Harrison G, Rowell NR, Hughes P. Antibody-dependent cytotoxicity of human vascular endothelium in systemic sclerosis. Clin Exp Immunol 1984;57:548-554.
254. Marks RM, Czerniecki M, Andrews BS, Penny R. The effects of scleroderma serum on human microvascular endothelial cells. Arthritis Rheum 1988;31:1524-1534.
255. Cockwell P, Tse WY, Savage COS. Activation of endothelial cells in thrombosis and vasculitis. Scand J Rheumatol (in press).
256. Lindsey NJ, Dawson RA, Henderson FJ, Greaves M, Hughes P. Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and anti-phospholipid syndrome. Br J Rheumatol 1993; 32:123-126.
257. Carreras LO, Machin SJ, Deman R, et al. Arterial thrombois, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;1:244-246.
258. Schorer AG, Wickham NWR, Watson KV. Lupus anticoagulant and thrombosis induces a selective defect in thrombin-mediated endothelial prostacyclin release and platelet aggregation. Br J Haematol 1989;71:399-407.
259. Watson KV, Schorer AE. Lupus anticoagulant inhibition of in vitro prostacyclin release is associated with thrombosis-prone subset of patients. Am J Med 1991;90:47-53.
260. Lindsey NJ, Henderson FI, Malia R, Milford-Ward MA, Greaves M, Hughes P. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and with the anti-phospholipid syndrome. Br J Rheumatol 1994;33:20-26.
261. Goldsmith JC, McCormick JJ. Immunologic injury to vascular endothelial cells: effects on release of prostacyclin. Blood 1984;63:984-989.
262. Coade SB, Van Haaren E, Loizou S, Walport MJ, Denman AM, Pearson JD. Endothelial prostacyclin release in systemic lupus erythematosus. Thromb Haemostasis 1989;61:97-100.
263. Walker S, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res 1988;51:267-281.
264. Cariou R, Tobelem G, Belluci S, et al. Effect of lupus anticoagulant and antithrombogenic properties on endothelial-inhibition of thrombomodulin-dependent protein C activation. Thromb Haemostasis 1988; 60:54-58.
265. Silver RK, Adler L, Hickman AR, Hagerman JR. Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am J Obstet Gynecol 1991;165:1748-1752.
266. Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: a possible mechanism of thrombosis. Am J Obstet Gynecol 1993;168: 206-210.
267. Tannenbaum SH, Finko R, Cines DB. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 1986;137:1532-1537.
268. Tannenbaum SH, Barnathan E, Vanderkeyl H, Kuo A, Murray S, Cines DB. Aggregated IgG stimulates the fibrinolytic inhibitory activity of human endothelial cells. Blood 1986;68:(Suppl):235.
269. Lee MJ, Silver RK, O'Connel PD, Caplan MS. Endothelial cell 1-acyl-platelet factor synthesis in response to anticardiolipin antibody-positive serum fractions. Prostaglandins 1994;47:221-231.
270. 2 activity. J Lab Clin Med 1992;120:10-16.
271. Borrell M, Sala N, Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipids antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemostasis 1992;68: 268-272.
272. Tsakiris DA, Settas L, Makris PE, Marbet GA. Lupus anticoagulant-antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 1990;17:785-789.
273. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995;95: 309-316.
274. Arnaud E, Lafay M, Gaussem P, et al. An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells and protein C activation. Blood 1994;84:1843-1850.
275. 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemostasis 1992;66:666-671.
276. Karmochkine M, Berard M, Piette JC, Cacoub P, Godeau P, Boffa MC. The effect of sera with antiphospholipid antibodies on endothelial cell procoagulant activity is dependent upon the charge of the phospholipids against which they are directed. Thromb Res 1994; 74: 435-440.
277. Chan TM, Frampton G, Perry GJ, Ravirajan CT, Isenberg DA, Cameron JS. Binding of anti-DNA antibodies to endothelial cells influences the expression of adhesion molecules. Lupus 1992;1:141(abstract).
278. Brinkman K, Termaat RM, de Jong J, van den Brink HG, Berden JHM, Smeenk RJT. Cross-reactive binding patterns of monoclonal antibodies to DNA are often caused by DNA/anti DNA immune complexes. Res Immunol 1989;140:595-603.
279. Chan TM, Yu PM, Tsang LC, Cheng IKP. Endothelial cell binding by human polyclonal anti-DNA antibodies: relationship to disease activity and endothelial functional alterations. Clin Exp Immunol 1995; 100:506-513.
280. Hosenpud JD, Shipley GD, Morris TE, Hefeneider SH, Wagner CR. The modulation of human aortic endothelial cell ICAM-1 (CD-54) expression by serum containing high liters of anti-HLA antibodies. Transplantation 1993;55:405-411.
281. Mayet WJ, Meyer zum Buschenfelde K-D. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993;94:3:440-446.
282. Mayet WJ, Schwarting A, Orth T, Duchmann R, Meyer zum Buschenfelde K-D. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996; 103:259-267.
283. Carvalho D, Savage COS, Black CM, Pearson JD. IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro: induction of adhesion molecule expression and involvement of endothelium-derived cytokines. J Clin Invest 1996;97:111-119.
284. Karmann K, Hughes CCW, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA 1995;92:4342-4346.
285. Nakamura N, Shidara Y, Kawaguchi N, et al. Lupus anticoagulant autoantibody induces apoptosis in umbilical vein endothelial cells: involvement of annexin V. Biochem Biophys Res Commun 1994;205: 1488-1493.
286. Cohen S, Johnson AS, Hurd E. Cytotoxicity of sera from patients with scleroderma. Arthritis Rheum 1983;26:170-178.
287. Matsuo S, Fakatsu A, Taub ML, Caldwell PRB, Brentjens JR, Andres G. Glomerulonephritis induced in the rabbit by antiendothelial antibodies. J Clin Invest 1987;79:1798-1811.
288. Camussi G, Pawlowski I, Bussolino F, Caldwell PRB, Brentjens J, Andres G. 1983. Release of platelet activating factor in rabbits with antibody-mediated injury of the lungs: the role of leukocytes and of pulmonary endothelial cells. J Immunol 1983;131:1802-1807.
289. Ito S, Hirabayashi K, Nielsen N, Ueda Y, Brentjens JR, Gans RO. Von Willebrand factor in the rat kidney: its localization and the effects of its in vivo interaction with specific antibodies. Nephron 1994;66:200-207.
290. Matsuda M. Experimental glomerular tissue injury induced by immunization with cultured endothelial cell plasma membrane. Acta Pathol Jpn 1988;38:823-839.
291. Abrass CK, Cohen AH. Characterization of renal injury initiated by immunization of rats with heparan sulfate. J Am Pathol 1988;130: 103-111.
292. Michalak E, Mathieson P, Cameron JS, Frampton G. Endothelial cell antibodies in an animal model of systemic vasculitis. Nephrol Dial Transpl 1992;7:765(abstract).
293. Blank M, Tomer Y, Stein M, et al. Immunization with anti-neutrophil cytoplasmic antibodies (ANCA) induces the production of mouse ANCA and perivascular lymphocyte infiltration. Clin Exp Immunol 1995;102:120-130.
294. Ates E, Bakkaloglu A, Saatci U, Soylemezoglu O. von Willebrand factor antigen compared with other factors in vasculitic syndromes. Arch Dis Child 1994;70:40-43.
295. Blann AD. von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease. J Rheumatol 1993;20: 1469-1471.
296. Ohdama S, Takano S, Miyake S, Kubota T, Sato K, Aoki N. Plasma thrombomodulin as a marker of vascular injuries in collagen vascular disease. Am J Clin Pathol 1994;101:109-113.
297. Matucci-Cerinic M, Pignone A, Lotti T. Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol 1990;17:328-330.
298. Godin-Ostro E, Mitrane M, Heller I, Kim HC, Seibold JR. Plasma plasminogen activator in systemis sclerosis. Arthritis Rheum 1985; 28(Suppl):S80.
299. Lau CS, McLaren M, Mackay I, Belch JJF. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. Ann Rheum Dis 1993;52:443-448.
300. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993;14(Suppl K):118-124.
301. Pall AA, Savage COS. Mechanisms of endothelial cell injury in vasculitis. Springer Semin Immunopathol 1994;16:23-37.
302. Jimenez SA, Bautman O. Immunopathogenesis of systemic sclerosis: possible role for retrovirus. Autoimmunity 1993;16:225-233.
303. Bolster MB, Silver RM. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1994;6:642-649.
304. Carson DA. Genetic factors in the etiology and pathogenesis of autoimmunity. Faseb J 1992;6:2800-2805.
305. Nabel EG, Plautz G, Nabel GJ. Transduction of a foreign histocompatibility gene into the arterial wall induces vasculitis. Proc Natl Acad Sci USA 1992;89:5157-5161.
306. Charles LA, Falk RJ, Jennette JC. Reactivity of antineutrophil cytoplasmic antibodies with mononuclear phagocytes. J Leukocyte Biol 1992;51:65-68.
307. 2 or products of activated neutrophils. Am J Med 1991;30(Suppl):3s-94s.
308. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365-375.
309. Savage CO, Gaskin G, Pusey CD, Pearson JD. 1993. Anti-neutrophil cytoplasm antibodies can recognize vascular endothelial cell-bound anti-neutrophil cytoplasm antibody-associated autoantigens. Exp Nephrol 1993;1:190-195.
310. van der Wal AC, Das PK, Tigges AJ, Becker AE. Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am J Pathol 1992;141:1427-1433.
311. Cerilli J, Brasile L, Karmody A. Role of the vascular cell antigen in the etiology of arteriosclerosis. Ann Surg 1985;202:329-334.
312. Khan BV, Parthasarathy SS, Alexander RW, Medford RM. Modified low density lipoprotein and its constituents augment cytokine-acti-vated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995;95:1262-1270.
313. Lehr HA, Olofsson AM, Carew TE, et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994;71:380-386.
314. Blake DR, Winyard P, Scott DGI, Brailsford S, Blann A, Lunec J. Endothelial cell cytotoxicity in inflammatory vascular diseases - the possible role of oxidised lipoproteins. Ann Rheum Dis 1985;44:176-182.
315. Thorin E, Hamilton CA, Dominiczak MH, Reid JL. Chronic exposure of cultured bovine endothelial cells to oxidized LDL abolishes prostacyclin release. Arteriosclerosis Thromb 1994;14:453-459.
316. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem 1995;270:319-324.
317. Malmsten CL. Prostaglandins, thromboxanes, and leukotrienes in inflammation. Am J Med 1986;80:11-17.
318. Lloyd AR, Oppenheim JJ. Poly's lament: the neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 1992;13:169-172.